Stuart Oliver

1.4k total citations
29 papers, 1.1k citations indexed

About

Stuart Oliver is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Stuart Oliver has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Pharmacology. Recurrent topics in Stuart Oliver's work include Pharmacogenetics and Drug Metabolism (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Stuart Oliver is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Stuart Oliver collaborates with scholars based in United Kingdom, United States and France. Stuart Oliver's co-authors include Kathleen Butler, Renli Teng, Martin A. Hayes, Lynn Purkins, Nolan Wood, Michael J. Allen, Chris Ward, Paul Martin, Jessica Read and Paul K. Stockman and has published in prestigious journals such as Blood, Gastroenterology and Journal of the American College of Cardiology.

In The Last Decade

Stuart Oliver

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stuart Oliver United Kingdom 17 290 268 246 232 216 29 1.1k
Michael Seiberling Switzerland 21 309 1.1× 221 0.8× 141 0.6× 198 0.9× 299 1.4× 45 1.6k
Anne Hulin France 21 321 1.1× 168 0.6× 35 0.1× 180 0.8× 224 1.0× 74 1.4k
Kazuko Kobayashi Japan 27 481 1.7× 94 0.4× 111 0.5× 94 0.4× 195 0.9× 89 2.0k
Brian P. Monahan United States 12 245 0.8× 295 1.1× 204 0.8× 47 0.2× 52 0.2× 22 931
Steve Riley United States 15 626 2.2× 195 0.7× 373 1.5× 59 0.3× 110 0.5× 40 1.2k
Anther Keung United States 14 178 0.6× 384 1.4× 36 0.1× 310 1.3× 193 0.9× 24 948
Julie Bullock United States 17 467 1.6× 515 1.9× 72 0.3× 76 0.3× 77 0.4× 26 1.6k
Thomas Papoian United States 14 428 1.5× 108 0.4× 229 0.9× 133 0.6× 89 0.4× 20 954
Hiroshi Maruyama Japan 20 339 1.2× 193 0.7× 322 1.3× 83 0.4× 101 0.5× 136 1.5k
Rongyue Teng United States 18 236 0.8× 157 0.6× 140 0.6× 36 0.2× 179 0.8× 37 848

Countries citing papers authored by Stuart Oliver

Since Specialization
Citations

This map shows the geographic impact of Stuart Oliver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Oliver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Oliver more than expected).

Fields of papers citing papers by Stuart Oliver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Oliver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Oliver. The network helps show where Stuart Oliver may publish in the future.

Co-authorship network of co-authors of Stuart Oliver

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Oliver. A scholar is included among the top collaborators of Stuart Oliver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Oliver. Stuart Oliver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Martín, Paul, Stuart Oliver, Michael Gillen, Thomas Marbury, & David Millson. (2015). Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies. Clinical Therapeutics. 37(12). 2823–2836. 11 indexed citations
3.
Martin, Paul, Michael Gillen, David Millson, et al.. (2015). Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies. Clinical Therapeutics. 37(12). 2811–2822. 15 indexed citations
4.
Johansson, Susanne, Jessica Read, Stuart Oliver, et al.. (2014). Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine. Clinical Pharmacokinetics. 53(9). 837–847. 52 indexed citations
5.
Kantarjian, Hagop M., Mikkael A. Sekeres, Vincent Ribrag, et al.. (2013). Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML. Clinical Lymphoma Myeloma & Leukemia. 13(5). 559–567. 46 indexed citations
6.
Kemp, John, et al.. (2011). Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers. Xenobiotica. 42(4). 363–371. 6 indexed citations
7.
Martín, Paul, et al.. (2011). Pharmacokinetics of Vandetanib: Three Phase I Studies in Healthy Subjects. Clinical Therapeutics. 34(1). 221–237. 67 indexed citations
8.
Martin, Paul, et al.. (2011). Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole. Drugs in R&D. 11(1). 37–51. 40 indexed citations
9.
Tomkinson, Helen, John Kemp, Stuart Oliver, et al.. (2011). Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. PubMed. 11(1). 3–3. 27 indexed citations
10.
11.
Martin, Paul, et al.. (2010). Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment. Clinical Pharmacokinetics. 49(9). 607–618. 26 indexed citations
12.
Teng, Renli, Stuart Oliver, Martin A. Hayes, & Kathleen Butler. (2010). Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects. Drug Metabolism and Disposition. 38(9). 1514–1521. 213 indexed citations
13.
Michael, Michael, Peter Gibbs, Robert P. Smith, et al.. (2008). Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Investigational New Drugs. 27(3). 253–261. 22 indexed citations
14.
He, Minxia M., Trent L. Abraham, Thomas J. Lindsay, et al.. (2003). Metabolism and Disposition of the Antihypertensive Agent Moxonidine in Humans. Drug Metabolism and Disposition. 31(3). 334–342. 7 indexed citations
15.
Purkins, Lynn, et al.. (2003). Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety. British Journal of Clinical Pharmacology. 56(s1). 10–16. 123 indexed citations
16.
Purkins, Lynn, et al.. (2003). The pharmacokinetics and safety of intravenous voriconazole – a novel wide‐spectrum antifungal agent. British Journal of Clinical Pharmacology. 56(s1). 2–9. 92 indexed citations
17.
Allen, Michael J., et al.. (2002). Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval. British Journal of Clinical Pharmacology. 53(1). 59–65. 9 indexed citations
18.
Iuliucci, John D., Stuart Oliver, Steven K. Morley, et al.. (2001). Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers. The Journal of Clinical Pharmacology. 41(8). 870–879. 98 indexed citations
19.
Allen, Michael J., Donald J. Nichols, & Stuart Oliver. (2000). The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing. British Journal of Clinical Pharmacology. 50(3). 247–253. 34 indexed citations
20.
Anders, Robert J., John C. Alexander, Gary Hantsbarger, et al.. (1995). 931-113 Demonstration of Potent Inhibition of Platelet Aggregation with an Orally Active GPllb/IIIA Receptor Antagonist. Journal of the American College of Cardiology. 25(2). 117A–117A. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Seiberling Breakdown of academic impact, for papers by Anne Hulin Breakdown of academic impact, for papers by Kazuko Kobayashi Breakdown of academic impact, for papers by Brian P. Monahan Breakdown of academic impact, for papers by Steve Riley Breakdown of academic impact, for papers by Anther Keung Breakdown of academic impact, for papers by Julie Bullock Breakdown of academic impact, for papers by Thomas Papoian Breakdown of academic impact, for papers by Hiroshi Maruyama Breakdown of academic impact, for papers by Rongyue Teng
Rankless by CCL
2026